John A. Morren

机构：Cleveland Clinic, The Neurological Institute · ORCID：0000-0002-9738-9547

发表论文 80 篇 · 总被引 1345 次 · h-index 13

代表论文

• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial (2021 · The Lancet Neurology · 被引 693)
• The role of artificial intelligence in electrodiagnostic and neuromuscular medicine: Current state and future directions (2023 · Muscle & Nerve · 被引 34)
• Myasthenia gravis: Frequently asked questions (2023 · Cleveland Clinic Journal of Medicine · 被引 32)
• Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis (2021 · Amyotrophic Lateral Sclerosis · 被引 30)
• Promising therapies for the treatment of myasthenia gravis (2024 · Expert Opinion on Pharmacotherapy · 被引 12)
• CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS) (2023 · Expert Opinion on Investigational Drugs · 被引 11)